Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 12/20 | 0.42 |
| ▸ | CCR9 | P51686 | 2/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | ATIC | P31939 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6022340 | 0.90 | SLC22A12 (0.56) | SLC22A12BRD4PKMARCCR9 | |
| SCHEMBL5761786 | 0.89 | PKM (0.52) | BRD4PKMPARP1AR | |
| SCHEMBL5761510 | 0.88 | FFAR1 (0.51) | BRD4PKMARGAA | |
| SCHEMBL5759891 | 0.86 | FFAR4 (0.48) | PKMAR | |
| SCHEMBL5763915 | 0.85 | SLC22A12 (0.49) | SLC22A12PKMAR | |
| SCHEMBL5761367 | 0.85 | SIRT2 (0.44) | PKMARGAA | |
| SCHEMBL5760368 | 0.85 | LMNA (0.50) | BRD4PKMAR | |
| SCHEMBL5761817 | 0.85 | L3MBTL1 (0.50) | PKMARGAA | |
| SCHEMBL5860305 | 0.84 | MAPT (0.51) | PKMARGAA | |
| SCHEMBL5861269 | 0.83 | AR (0.47) | PKMARGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098340-B2 | Quinoline/chromene derivatives as androgen antagonist | WARNER LAMBERT COMPANY LLC (US) | 2006-08-29 | — | — | US | claimed |
| US-20050137228-A1 | Benzyl sulfonamide derivatives | DU DANIEL Y (US) | 2005-06-23 | — | — | US | claimed |
| US-7098340-B2 | Quinoline/chromene derivatives as androgen antagonist | WARNER LAMBERT COMPANY LLC (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050137228-A1 | Benzyl sulfonamide derivatives | DU DANIEL Y (US) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137228-A1 | Benzyl sulfonamide derivatives | AR, SHBG, BRDT | SLC22A12 1909/4885BRD4 39/4885PKM 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.